<DOC>
	<DOCNO>NCT00918580</DOCNO>
	<brief_summary>This study evaluate safety , tolerability immunogenicity 13-valent pneumococcal Conjugate Vaccine child Sickle Cell Disease already vaccinate 23-valent polysaccharide vaccine . The study measure amount antibody ( protein fight germ ) produce child Sickle Cell Disease give 13-valent pneumococcal vaccine 6 less 18 year age . They give vaccination twice , vaccination separate approximately 6 month .</brief_summary>
	<brief_title>Study Evaluating 13-valent Pneumococcal Conjugate Vaccine ( 13vPnC ) Children With Sickle Cell Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male female subject age &gt; =6 &lt; 18 year . Diagnosis SCD 23vPS vaccination least 6 month prior enrollment . Previous vaccination pneumococcal conjugate vaccine . Previous reaction vaccine vaccinerelated component contraindication vaccination pneumococcal conjugate vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>